The increasing prevalence of OSA and the increasing number of patients with T2D and prediabetes suggest that evaluating the therapeutic interaction of GABA with insulin-secretion processes under IH conditions is an urgent public health issue. This evidence concerns the gene INS and prediabetes syndrome.